DB16808InvestigationalGene Therapies
Isaralgagene civaparvovec, formerly known as ST-920, is liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase A (α-Gal A) enzyme. It is developed by Sangamo Therapeutics and investigated in...
- Code names
- ST-920
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Isaralgagene civaparvovec, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account